Binding of galectin-3 to cell surface glycans also promotes the formation of an inflammatory and fibrotic environment within the tumour (Bouffette et al. 2023) that supports tumour growth and resistance to cancer therapeutic treatments including chemo-, radio-, and immune-therapies (Navarro et al. 2020). Here, LGALS3 is linked to cancer.